Drug Safety Board Is Biased By Connection To CDER, Sen. Grassley Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Grassley is asking FDA to outline the specific steps that will be taken to ensure the independence of the committee. A letter to FDA Acting Commissioner Crawford was released the same day the Institute of Medicine convened its meeting to study FDA’s drug safety review practices.
You may also be interested in...
CDER Drug Safety Oversight Board To Receive Unprecedented External Input, Galson Says
The Center for Drug Evaluation & Research's Drug Safety Oversight Board will include an unprecedented level of external input, CDER Acting Director Steven Galson said
CDER Drug Safety Oversight Board To Receive Unprecedented External Input, Galson Says
The Center for Drug Evaluation & Research's Drug Safety Oversight Board will include an unprecedented level of external input, CDER Acting Director Steven Galson said
Drug Safety Oversight Board Will Require Two-Thirds Majority For Recommendations
FDA's Drug Safety Oversight Board will need a two-thirds majority of a quorum to make recommendations, a Center for Drug Evaluation & Research Manual of Policies & Procedures states